The therapeutic landscape in melanoma is evolving rapidly. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) interviews Dr Teresa Amaral (the current chair of the ESMO Young Oncologists Committee and an expert in melanoma) for an update on the current practice and advances in adjuvant and neoadjuvant therapies in melanoma.

Dr Amaral summarises key practice-changing studies which have established the current recommendations in this field, including CheckMate 238, KEYNOTE 054, COMBI-AD, Combi-Neo, NeoCombi and opACIN-neo. We also deliberated on the toxicity profile of these therapies, and currently available evidence of neoadjuvant versus adjuvant therapies. Finally, we addressed how COVID-19 has affected the delivery of adjuvant and neoadjuvant therapies in patients with melanoma.

Further reading {#s1}
===============

-   CheckMate 238 -- <https://doi.org/10.1056/NEJMoa1709030>

-   KEYNOTE 054 -- <https://doi.org/10.1056/NEJMoa1802357>

-   EORTC18071 -- <https://doi.org/10.1016/S1470-2045(15)70122-1>

-   Mixture-Cure Modelling in CheckMate 238 -- <https://doi.org/10.1093/annonc/mdz255>

-   COMBI-AD -- <https://doi.org/10.1056/NEJMoa1708539>

-   Combi-Neo -- <https://doi.org/10.1016/S1470-2045(18)30015-9>

-   NeoCombi -- <https://doi.org/10.1016/S1470-2045(19)30331-6>

-   OpACIN-neo -- <https://doi.org/10.1016/S1470-2045(19)30151-2>
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